ArticleJournal of nephrology2025
Frailty compared to sarcopenia as the predictor of mortality for elderly hemodialysis patients.
Article in Journal of nephrology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Changes in frailty and all-cause mortality in patients on hemodialysis: a prospective cohort study.BMC nephrology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundHemodialysis (HD) patients are at an increased risk of sarcopenia and related mortality. As the number of elderly patients with chronic kidney disease (CKD) undergoing HD continues to grow, the prevalence of frailty also rises. This study aims to assess whether frailty or sarcopenia constitutes a greater risk to patient survival.
methodsA single-center cohort of HD patients was followed for four years. Clinical frailty scores and body composition, assessed using multifrequency bioelectrical impedance analysis, were utilized to evaluate survival outcomes.
resultsAmong 173 HD patients, mean age 64.7 ± 15.6 years, 102 (58.9%) male, 31 (17.9%) diabetic, 66 (38.1%) were sarcopenic, and 132 (76.3%) were frail. Kaplan-Meier analysis revealed no significant differences in survival between patients categorized as non-obese and non-sarcopenic, obese and non-sarcopenic, non-obese and sarcopenic, or obese and sarcopenic. However, frail patients showed significantly higher mortality. Multivariable logistic regression analysis identified frailty as an independent predictor of mortality (hazard ratio [HR] 2.1, 95% confidence interval [CI] 1.2-3.6, p = 0.004), while sarcopenia was not statistically significant (HR 1.01, 95% CI 0.83-1.25, p = 0.86).
conclusionFrailty, rather than sarcopenia, was associated with mortality in HD patients. While multifrequency bioelectrical impedance analysis requires specialized equipment, clinical frailty scores offer a rapid and cost-effective screening tool.
Indexed as
Identifiers
40835786What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.